16
Ascletis Pharma Inc.
1672.HK · HKSE
$9.76 -2.94% (-$0.30)
1M -6.16%
Market Cap ¥9.03B
P/E Ratio -
Div. Yield -
ROE 17.91%
Piotroski F-Score Weak
1/9Valuation
21 /100
Expensive P/B 4.67x
P/S 4,454.14x
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 8.67%
Rev. growth 66.53%
FCF growth N/A
Profitability
9 /100
Weak Op. margin 23,853.90%
Gross margin 25.99%
FCF margin 16,312.90%
Quality
0 /100
Poor ROA 17.41%
ROIC 24.97%
Asset turnover 0.00x
Debt
69 /100
Low Int. coverage -2,954.46x
Debt/Equity 0.00x
Current ratio 15.05x
Stability
13 /100
Unstable EPS volatility 93.35%
Beta 0.39x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about 1672.HK
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jinzi J. Wu
Employees
202
Headquarters
Hong Kong
Upcoming events
30 MAR
Earnings
Upcoming earnings report